Back to News
Market Impact: 0.25
Orvida Pharma Announces Interim Financing Led by Recordati to Advance Ontivatrep Development for Rare Genetic Skin Diseases
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Proceeds from an unspecified financing will support continued clinical development of ontivatrep, an oral TRPV3 inhibitor. The company expects Phase 1b topline data in Olmsted syndrome by the end of 2026, providing a defined near-term clinical catalyst.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
More News
- Nasdaq Nears Correction as Amazon, Alphabet, Intel Disappoint Wall Street
- Binance’s $6.3 Billion Cyber Heist Shows Crypto Vulnerabilities
- Big Oil Scores $56 Billion Windfall on Spiking Fuel Prices
- Chevron speeds ahead in Venezuela while Exxon urges caution with a ‘little pinch of salt’
- Backbone of a beast – charting Nvidia's rise to networking titan
- OpenAI raises just $11bn of $30bn target as AI investor appetite cools